<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-044561</identifier>
<setSpec>0034-0618</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Thalidomide: a new view of an old toxic</dc:title>
<dc:description xml:lang="en">Since the early 60s, when thalidomide was withdrawn from markets, this drug ;;has been widely studied due to its teratogenic activity. The finding of new therapeutic properties has raised a new interest in this molecule, and recently the FDA ;;has approved its use in the treatment of ENL (Erythema Nodosum Leprosum), an ;;acute manifestationof leprae. Besides, thalidomide is nowadays going through clinical ;;assays (PhaseII/III) in multiple myeloma, breast, prostate, kidney and lung ;;tumours, showing good results. This article offers an overview of thalidomide ;;properties focusing on its inhibition of angiogenesis, which would be responsible, ;;at least partially, of its antineoplastic and teratogenic activity</dc:description>
<dc:creator>Martín-Cantalejo, Yolanda</dc:creator>
<dc:creator>Fernández Braña, Miguel</dc:creator>
<dc:creator>Morán, Marina</dc:creator>
<dc:creator>Añorbe, Loreto</dc:creator>
<dc:creator>López Sáez, Berta</dc:creator>
<dc:creator>Miguel, Pilar de</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Desde que a principios de los años 60 la talidomida fuera retirada del mercadodebido a su acción teratogénica, este fármaco ha sido ampliamente estudiado,encontrándose en él propiedades terapéuticas que han despertado nuevamente elinterés por esta molécula. Recientemente, la FDA ha aprobado su empleo en eltratamiento de ENL (Erythema Nodosum Leprosum), una manifestación aguda dela lepra. Además, actualmente se encuentra en ensayos clínicos (fase II/III) enmieloma múltiple, cáncer de mama, próstata, riñón y pulmón, mostrando buenosresultados. En este artículo se ofrece una visión general de las propiedades de latalidomida, haciendo especial hincapié en su acción inhibitoria de la angiogénesis,que podría ser responsable, al menos en parte, de su actividad antineoplásica yteratogénica</dc:description>
<dc:source>An Real Acad Farm;70(4): 885-904, oct. 2004. ilus</dc:source>
<dc:identifier>ibc-044561</dc:identifier>
<dc:title xml:lang="es">Talidomida: una visión nueva de un tóxico antiguo</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d2672^s22034</dc:subject>
<dc:subject>^d2672^s22045</dc:subject>
<dc:subject>^d38326^s29165</dc:subject>
<dc:subject>^d14171^s29165</dc:subject>
<dc:subject>^d34460^s29165</dc:subject>
<dc:subject>^d38327^s22078</dc:subject>
<dc:subject>^d14171^s22078</dc:subject>
<dc:subject>^d14171^s22034</dc:subject>
<dc:subject>^d9562^s22057</dc:subject>
<dc:subject>^d14171^s22079</dc:subject>
<dc:subject>^d974^s22078</dc:subject>
<dc:subject>^d14171^s22065</dc:subject>
<dc:subject>^d38326^s22078</dc:subject>
<dc:subject>^d14171^s22073</dc:subject>
<dc:subject>^d34460^s22078</dc:subject>
<dc:subject>^d974^s22073</dc:subject>
<dc:type>article</dc:type>
<dc:date>200410</dc:date>
</metadata>
</record>
</ibecs-document>
